Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Tissue sections of frozen biopsy specimens obtained from normal and hyperplastic human lymphoid tissues as well as 40 cases of non-Hodgkin's lymphomas were analysed in immunofluorescence tests (using red TRITC and green FITC double-labeling). A panel of antisera including well-characterized conventional reagents to immunoglobulin classes, T-lymphoid and Ia-like antigens and monoclonal antibodies, including the OKT range made by Ortho Laboratories, was used. The findings show that the immunological methods can give a very accurate analysis of the normal and malignant lymphoid cells and can provide complementary information to conventional histology. Furthermore, the monoclonal antibodies to well defined lymphocyte subsets can provide data which suggests (although does not prove) functional relationships between different types of cells in normal and malignant lymph nodes. Thus, the technology described fills the gap between conventional histology and cellular immunology.
 ...
PMID:The analysis of lymphoid subpopulations in normal and malignant tissues by immunofluorescence techniques. 645 70

The study objective was to determine if suppression of ovarian function by oral contraceptives (OCs) would provide protection against ovarian cell death secondary to chemotherapy. By means of menstrual history, serum gonadotropin levels, and ovarian biopsy, ovarian function was evaluated in 6 young women with untreated Hodgkin's disease. The women ranged in age from 18 to 31 years at onset of treatment. Each woman was given a standard 6 cycles of MVPP therapy (nitrogen mustard, vinblastine, procarbazine, and prednisone). At the time of initiation of MVPP therapy, they were placed on the combination OCs Norlestrin or Ovran on the usual schedule for birth control. 6-12 weeks after the last cycle, 3 women were biopsied and the menstrual history was repeated in all cases. This followup was repeated at intervals of 4-12 months, the most recent in April 1981, range 20-29 months, median 26 months. 5 ovarian biopsies obtained prior to therapy contained 18-55 primordial and primary follicles. Posttherapy ovarian biopsies were performed on 3 of the 6 women who had been treated with OC while they were receiving the 6 cycles of MVPP therapy. The ovary specimens revealed 22, 1000, and 22 primordial and primary follicles per section. Normal menses were established in the 5 women who discontinued OCs at the end of MVPP therapy, and 1 of them is currently pregnant. The pregnancy and the regular menses in the 3 women not on hormonal agents up to 2 years after stopping MVPP therapy encourages the belief that these women will not experience premature menopause in a few years' time. Particularly hopeful is the normal ovarian function of the 30-year-old woman, the woman who was at greatest risk for chemotherapy-induced ovarian failure.
 ...
PMID:Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's disease. 727 13